CCR2 is a potential biomarker and therapeutic target in Group 3 medulloblastoma
Carlos Custodia, Rita Cascão, Eunice Paisana, Daniel Picard, Pedro Ruivo, Tiago Rodrigues, Inês Lourenço, Sofia Nunes, Nan Qin, Luisa Albuquerque, Rafael Roque, José Miguéns, Marc Remke, Joao T. Barata, Claudia C Faria
This study identifies CCR2 as a biomarker and therapeutic target in Group 3 medulloblastoma, showing its association with dissemination and poor survival, and demonstrating therapeutic efficacy through Cenicriviroc.
bioRxiv · Oct 13, 2026 · PreprintCancer Biology